Drug recall: Rifampin Capsules recalled due to this reason

The affected lot has been produced at Lupin's Aurangabad plant and marketed in the US by Baltimore-based Lupin Pharmaceuticals.

250
Drug recall

Last Updated on January 23, 2023 by The Health Master

New Delhi: Drug maker Lupin is recalling 16,056 bottles of Rifampin Capsules, used in the treatment of all forms of tuberculosis, in the US market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).

As per the latest Enforcement Report by the US health regulator, Lupin Pharmaceuticals Inc, a US-based arm of the Mumbai-based drug major, is recalling the affected lot due to “Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.”

The affected lot has been produced at Lupin’s Aurangabad plant and marketed in the US by Baltimore-based Lupin Pharmaceuticals.

The company initiated Class II nationwide (US) recall of the affected lot on December 12 last year.

As per the US Food and Drug Administration (USFDA), a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

The US generic drug market was estimated to be around USD 115.2 billion in 2019. It is the largest market for pharmaceutical products.

Drug recall: Epinephrine API recalled due to this reason

Drug recall: Daptomycin for Injection recalled due to this reason

Drug recall: Vancomycin Hydrochloride Injection recalled due to this reason

Drug recall: 4 lots of Quinapril Tablets recalled due to this reason

Drug recall: This Blood Pressure tablets recalled

Drug recall: Sodium Bicarbonate Injection recalled due to this reason

Fraud in MBBS admissions: High Court stays acquittal

Nutraceutical industry trends will rule the year

Govt to introduce incentive scheme to boost R&D by pharma industry:…

USFDA gives tentative approval Acalabrutinib capsules, 100 mg

NPPA revised Ceiling price of 111 scheduled formulations: January 2023

NABL asks laboratories to make fresh registrations in new NABL portal

Drug alert: 70 out of 1375 samples declared as NSQ in December 2022

USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets

DCGI approves Covovax as booster dose

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news